List of Excipients in Branded Drug IWILFIN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
USWM LLC	IWILFIN	eflornithine hydrochloride	78670-150	CELLULOSE, MICROCRYSTALLINE	2030-12-13
USWM LLC	IWILFIN	eflornithine hydrochloride	78670-150	MAGNESIUM STEARATE	2030-12-13
USWM LLC	IWILFIN	eflornithine hydrochloride	78670-150	SILICON DIOXIDE	2030-12-13

IWILFIN Excipient Strategy and Commercial Opportunities in Eflornithine Hydrochloride

Last updated: October 5, 2026

IWILFIN is an oral eflornithine hydrochloride tablet approved by the FDA for maintenance treatment of pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior multimodal therapy. Its commercial opportunity is concentrated in orphan oncology, where dosing is weight-based, treatment duration can be prolonged, and the patient population is small but medically concentrated.

The strongest excipient opportunities are pediatric administration, dose flexibility, swallowability, palatability, stability, and lower-burden packaging. A generic competitor is more likely to challenge the tablet through a conventional ANDA pathway than through biosimilar development. Formulation differentiation could support lifecycle management, but regulatory and patent value will depend on whether a new product solves a clinically relevant administration problem.

What is IWILFIN and how is it administered?

IWILFIN contains eflornithine hydrochloride and is supplied as 192 mg film-coated tablets. The product is administered orally at a weight-based daily dose, with the total daily dose divided into two doses. The FDA label permits dose calculation by body weight and caps the daily dose at 400 mg/kg.[1]

Attribute	IWILFIN
Active ingredient	Eflornithine hydrochloride
Strength	192 mg per tablet
Dosage form	Film-coated tablet
Route	Oral
FDA indication	Maintenance treatment of pediatric patients with high-risk neuroblastoma
Population	Pediatric oncology patients after response to prior therapy
Dosing basis	Weight-based
Maximum labeled dose	400 mg/kg/day
Approval date	December 15, 2023
Regulatory category	Orphan drug product
Manufacturer	US WorldMeds, LLC

The high maximum dose creates a tablet-burden issue. A 30 kg patient receiving 400 mg/kg/day would require 12,000 mg of eflornithine hydrochloride daily, equivalent to approximately 63 tablets at 192 mg each before accounting for rounding and actual prescribed dosing. The labeled regimen is individualized, so tablet counts vary materially by body weight and treatment phase.

This dosing profile makes formulation strategy commercially important. A product that reduces tablet count, improves administration to younger children, or allows reliable dosing for patients unable to swallow tablets could address a practical limitation of the reference product.

What excipients are used in IWILFIN tablets?

The FDA prescribing information identifies the inactive ingredients in IWILFIN as colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, talc, and titanium dioxide.[1]

Excipient	Likely formulation function
Microcrystalline cellulose	Diluent and tablet-bulk material
Sodium starch glycolate	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant
Hypromellose	Film-coating polymer
Talc	Coating aid and anti-tacking agent
Titanium dioxide	Opacifier and coating pigment

The formulation is consistent with a conventional immediate-release, film-coated tablet. The excipient system appears designed to support manufacturability, mechanical strength, disintegration, and coating performance rather than pediatric taste optimization.

The public label does not indicate that IWILFIN is chewable, dispersible, orally disintegrating, sprinkleable, or supplied as an oral liquid. That creates a defined lifecycle-management opportunity, although the clinical value of a new dosage form must be established in the target pediatric population.

Which excipient strategies offer the strongest commercial opportunity?

Pediatric liquid and dispersible formulations

The highest-value opportunity is a liquid, suspension, or dispersible formulation for children who cannot reliably swallow tablets. A liquid formulation could reduce caregiver burden and support administration in younger patients, patients with treatment-related mucositis, and patients with feeding tubes.

Eflornithine hydrochloride is highly water soluble, which can support liquid development. Solubility alone does not resolve the main development issues. A liquid product would require control of:

• Chemical and physical stability
• Taste and mouthfeel
• Dose uniformity after storage
• Preservation strategy
• Container compatibility
• Tube-administration performance
• In-use shelf life
• Microbial limits
• Measurement-device accuracy

A suspension could provide higher drug loading or better taste masking than a true solution, but it would require validated redispersibility and dose uniformity. A solution would simplify dose withdrawal but may expose the patient to stronger bitterness and greater chemical-stability demands.

Lower-strength tablets

Lower-strength tablets could reduce dose-rounding errors and improve administration for smaller children. Potential strengths might include 25 mg, 50 mg, or 100 mg equivalents, subject to dose-calculation requirements and manufacturing economics.

A lower-strength product has several commercial advantages:

1. More accurate weight-based dosing.
2. Lower tablet burden for some dosing schedules if used in combination.
3. Better suitability for dose titration.
4. Reduced need for tablet splitting.
5. Improved compatibility with pediatric dosing protocols.

The main limitation is manufacturing complexity. Multiple strengths increase inventory, packaging, stability, and supply-chain requirements. A single 192 mg tablet remains operationally simpler for a rare-disease product unless clinical demand supports multiple presentations.

Orally disintegrating and mini-tablet formats

Orally disintegrating tablets and mini-tablets could address swallowing difficulties without introducing a liquid product. These systems would require attention to:

• Bitter taste exposure during disintegration
• Friability
• Moisture sensitivity
• Packaging protection
• Dose flexibility
• Mouthfeel
• Acceptability in very young children

Mini-tablets may offer a practical compromise between tablet and liquid administration. They can be administered directly or dispersed in a small volume of compatible liquid, provided the product labeling supports that use.

Taste-masked formulations

Eflornithine is expected to require taste-masking work in any dosage form that dissolves or disintegrates in the mouth. Relevant approaches include polymeric taste-masking coatings, ion-exchange resins, lipid barriers, complexation, and flavor systems.

Taste masking should be treated as a clinical performance attribute rather than a cosmetic improvement. Poor palatability can lead to missed doses during prolonged maintenance treatment. A successful formulation would need pediatric acceptability data, not only laboratory dissolution results.

Tablet-size and dose-density optimization

A higher-strength tablet could reduce the number of units required per day. The commercial benefit is constrained by tablet size, swallowability, and dose rounding. A larger tablet may be unacceptable for young patients even if it improves caregiver convenience.

Dose-density optimization is more likely to support an improved product when combined with another feature, such as a scored tablet, a dispersible tablet, or a small-format high-load tablet.

How does the current excipient system compare with lifecycle-management options?

Product concept	Primary excipient objective	Commercial value	Key technical risk
Current film-coated tablet	Manufacturability and immediate release	Established reference product	High tablet burden
Lower-strength tablet	Dose flexibility	Moderate	More SKUs and supply complexity
Oral solution	Accurate liquid dosing	High for non-swallowing patients	Taste, stability, preservation
Oral suspension	High drug loading and liquid delivery	High	Uniformity and redispersibility
Orally disintegrating tablet	No-water administration	Moderate to high	Bitterness and moisture sensitivity
Mini-tablet	Pediatric administration	Moderate	Dose handling and patient acceptance
Sprinkle formulation	Administration with food or soft vehicle	Moderate	Food compatibility and labeling
Higher-strength tablet	Reduced unit count	Moderate	Tablet size and dose rounding

The most defensible commercial sequence would be an oral liquid or dispersible product followed by lower-strength or mini-tablet presentations. A simple reformulation using a different filler or lubricant would have limited commercial differentiation unless it materially improves dissolution, stability, or patient use.

What FDA regulatory pathway applies to IWILFIN formulation changes?

A new formulation of eflornithine could proceed through different FDA pathways depending on the applicant’s relationship to the reference product, the proposed dosage form, and the extent of clinical and bioequivalence data.

An ANDA may be available for a generic product that matches the reference product in dosage form, strength, route, conditions of use, and other applicable requirements. A materially different dosage form, such as an oral solution or orally disintegrating product, may require a 505(b)(2) application rather than a conventional ANDA.

A 505(b)(2) strategy can be commercially attractive where the applicant relies partly on FDA findings for eflornithine but introduces a new formulation, dosage form, administration method, or labeling element. The development program would likely need to address pharmacokinetics, dose proportionality, relative bioavailability, stability, and pediatric administration.

The FDA’s approval of IWILFIN does not make every later eflornithine product interchangeable with IWILFIN. Substitutability depends on the approved application, dosage form, strength, labeling, and state pharmacy law.

What patents and exclusivity protect IWILFIN?

IWILFIN benefits from orphan-drug exclusivity associated with its neuroblastoma indication. The seven-year orphan exclusivity period generally runs from the date of approval, placing the nominal end of the period in December 2030, subject to the statutory scope of exclusivity and any applicable regulatory developments.[2]

Orphan exclusivity is indication-specific. It does not create a blanket prohibition on every eflornithine product. Its practical effect depends on whether a competing product is directed to the same disease or condition and whether it uses the same active moiety.

Eflornithine is an established active ingredient with historical uses outside IWILFIN’s neuroblastoma indication. That reduces the likelihood that conventional new-chemical-entity exclusivity will be the primary commercial barrier. The principal protection is more likely to come from orphan exclusivity, method-of-use claims, formulation claims, regulatory data, manufacturing know-how, and commercial execution.

A current FDA Orange Book review is required to determine the exact listed patent numbers, use codes, and expiration dates associated with IWILFIN. Public product materials alone do not establish a complete patent position. Any diligence should separate:

• Patents covering eflornithine use in neuroblastoma
• Formulation patents
• Dosage-regimen claims
• Patient-selection claims
• Manufacturing and process patents
• Orange Book-listed patents
• Non-listed platform or trade-secret protection

When could generic or alternative eflornithine products enter?

The most important commercial dates are the FDA approval date and the end of orphan exclusivity. The timeline is:

Event	Date or period
FDA approval of IWILFIN	December 15, 2023
Nominal seven-year orphan exclusivity end	December 15, 2030
Potential earlier entry	Patent invalidity, non-infringement, regulatory exception, or different indication
Potential later entry	Valid unexpired patents, pediatric exclusivity, injunction, or regulatory delay

A Paragraph IV challenge could arise before patent expiry if a generic applicant certifies that listed patents are invalid, unenforceable, or not infringed. A Paragraph IV certification can trigger patent litigation and, in some circumstances, a 30-month stay of approval under the Hatch-Waxman framework.[3]

The orphan-exclusivity analysis is separate. A Paragraph IV certification does not automatically eliminate orphan exclusivity. A generic applicant would need to assess whether the proposed label overlaps the protected neuroblastoma indication and whether the product fits the statutory orphan-exclusivity exceptions.

Is biosimilar competition relevant to IWILFIN?

No. IWILFIN is a small-molecule drug, not a biologic. Biosimilar and interchangeable-biologic pathways do not apply. Competitive entry would occur through small-molecule pathways, including an ANDA or, for a materially different formulation or indication, a 505(b)(2) application.

The relevant competitors are therefore:

• Generic eflornithine tablets
• Alternative eflornithine oral formulations
• Compounded liquid preparations, where legally permitted
• Products using different excipient systems
• Potentially different maintenance strategies in neuroblastoma

Compounded preparations can create practical competition but do not generally provide the same FDA-approved labeling, manufacturing controls, stability package, or substitution status as an approved product.

What litigation, settlement, and licensing issues affect IWILFIN?

No major public Paragraph IV litigation or settlement agreement is established in the core FDA approval materials cited here. That status should not be interpreted as evidence that no future challenge will occur. A challenge would be most likely as orphan exclusivity approaches expiration or if the Orange Book contains commercially meaningful method-of-use or formulation patents.

The commercial ownership structure also matters. US WorldMeds is the listed sponsor and manufacturer of IWILFIN. A licensing or co-development transaction could focus on:

• Pediatric liquid development
• International distribution
• Manufacturing scale-up
• Regional commercialization rights
• Formulation patents
• Companion diagnostic or neuroblastoma-support services

No public revenue figure is established in the cited FDA materials. Commercial forecasting should therefore use patient numbers, treatment duration, weight-based dose, adherence, payer coverage, and net price rather than rely on reported product sales.

How strong is the IWILFIN formulation estate?

The visible formulation position is moderate rather than inherently strong. The approved tablet uses common pharmaceutical excipients and does not, based on the public label, present a complex delivery platform. Conventional excipient substitution would be difficult to defend broadly because the ingredients are widely used.

The stronger protection opportunities are clinically anchored claims covering:

• A specific pediatric liquid formulation
• Improved stability at high eflornithine concentration
• Taste masking with demonstrated pediatric acceptability
• Administration through feeding tubes
• A defined weight-based dosing system
• Reduced tablet burden
• A dispersible or mini-tablet product
• A formulation with improved adherence or reduced dosing error

Trade-secret protection may be important for taste-masking processes, suspension manufacture, preservative systems, and scale-up parameters. Those protections would not prevent independent development of a competing formulation but could raise manufacturing barriers.

What are the highest-value commercial opportunities?

The most attractive opportunities rank as follows:

1. A stable, palatable oral liquid for patients unable to swallow tablets.
2. A dispersible or mini-tablet dosage form for younger children.
3. Lower-strength tablets that improve weight-based dose accuracy.
4. A high-strength tablet that reduces unit burden without becoming too large to swallow.
5. Pediatric packaging with oral syringes, dose-calculation tools, and adherence support.
6. International formulations adapted to local pediatric administration practices.

Packaging is part of the commercial strategy. Unit-dose or calendar packaging could reduce medication errors in a complex maintenance regimen. Child-resistant packaging, moisture control, oral dosing syringes, and clear weight-based instructions may provide more practical value than a minor excipient change.

Key Takeaways

• IWILFIN is a 192 mg eflornithine hydrochloride film-coated tablet for pediatric high-risk neuroblastoma maintenance therapy.
• Its labeled weight-based dosing can create substantial tablet burden, especially at higher body weights.
• The current excipient system supports a conventional immediate-release tablet but does not appear optimized for pediatric palatability or liquid administration.
• Oral liquids, suspensions, dispersible tablets, mini-tablets, and lower-strength tablets are the main lifecycle opportunities.
• Orphan exclusivity is nominally expected to run through December 15, 2030, subject to the statutory scope and other exclusivity provisions.
• IWILFIN is not subject to biosimilar competition. Generic and alternative-formulation entry would use small-molecule pathways.
• Broad excipient claims are likely to be weak unless tied to stability, taste masking, dose accuracy, administration, or a demonstrated clinical benefit.
• Revenue exposure is difficult to quantify from public FDA materials because product sales and net pricing are not provided there.

FAQs

Can IWILFIN tablets be crushed or dissolved for children?

The FDA label does not establish unrestricted crushing, dissolution, or dispersion instructions. Such administration should not be treated as an approved use unless supported by product-specific labeling or validated clinical instructions.

Does IWILFIN have pediatric exclusivity in addition to orphan exclusivity?

The core FDA approval materials identify orphan-drug protection. A definitive pediatric-exclusivity determination requires review of the FDA exclusivity records and approval history.

Would an eflornithine oral solution automatically be substitutable for IWILFIN?

No. A different dosage form would require its own FDA approval and would not automatically receive pharmacy-level substitution status with the IWILFIN tablet.

Can a generic manufacturer use the same inactive ingredients as IWILFIN?

Yes, subject to applicable FDA requirements. Matching excipients does not by itself establish bioequivalence, therapeutic equivalence, or freedom to operate.

Is a taste-masked eflornithine formulation commercially patentable?

Potentially. Patent strength would depend on the claimed composition, measurable performance, inventive step, written description, enablement, and whether the formulation provides a clinically relevant advantage over known eflornithine products.

References

1. U.S. Food and Drug Administration. (2023). IWILFIN (eflornithine hydrochloride) tablets, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216197s000lbl.pdf

2. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs

3. U.S. Food and Drug Administration. (2024). Patent certification and the 30-month stay under the Hatch-Waxman Act. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-approval

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/ georgia?_ts=1731523016